e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Prognostic factors and subtyping of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers
G. Vavougios, T. Kerenidi, I. Tsilioni, K. Gourgoulianis (Larissa, Greece)
Source:
Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Session:
Prognostic factors and subtyping of lung cancer
Session type:
Thematic Poster Session
Number:
2914
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Vavougios, T. Kerenidi, I. Tsilioni, K. Gourgoulianis (Larissa, Greece). The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers. Eur Respir J 2013; 42: Suppl. 57, 2914
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Challenges in the management of SCLC
Related content which might interest you:
Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013
The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013
Reactive oxygen species modulator 1 (Romo1) as a diagnostic marker for lung cancer-related malignant effusion
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Role of Dr-70 immunoassay in suspected malignant pleural effusion
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Serum osteopontin as a prognostic marker in patients with lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Activated KRAS signaling triggers malignant pleural effusion
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Serum and bronchial aspiration fluid HE-4 levels in lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Expression and clinical significance of S100 calcium binding protein A2 in lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Survival of non small cell lung carcinoma patients with malignant pleural effusions
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Predictive parameters of survival in malignant pleural effusion
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015
The evaluation of biological and clinical significance of alpha-1 antitrypsin in non-small cell lung cancer
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Pleural eicosanoids in patients with lung cancer
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough?
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
LATE-BREAKING ABSTRACT: A proteomic study of benign and malignant pleural effusions
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Osteopontin levels in sputum supernatant and serum of patients with lung cancer: Does coexistent COPD make the difference?
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013
MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept